Compare DexCom, Inc. (DXCM) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs L3Harris Technologies Inc — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while L3Harris Technologies Inc trades at $237 (market cap $44.12B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays a 2.11% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and L3Harris Technologies Inc for 56 Days on average.
| DXCM | LHX | |
|---|---|---|
Market Cap | $31.86B | $44.12B |
Volume | 3,607,070 | 1,202,852 |
Sector | Health | Industrials |
52-Week High | $92.34 | $378.48 |
52-Week Low | $54.84 | $233.63 |
Typical Hold Time | 62 Days | 56 Days |
Enterprise Value | $31.32B | $54.56B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
LHX trades at $236.97, up 1.43% today, with a bearish technical signal despite strong fundamentals. The company reported revenue of $21.87B in 2025, with net income of $1.61B and improving profit margins. Recent contract wins, including a $6B THAAD propulsion deal with Lockheed Martin, highlight growth prospects. However, multiple law firm investigations into the company have emerged in September 2026, creating investor uncertainty.
The outlook is mixed: analyst consensus is bullish with a $340 price target, but technical indicators and legal overhangs pose risks. Earnings beats in recent quarters support fundamental strength, yet sentiment is tempered by bearish momentum and potential legal liabilities. Upside depends on contract execution and resolution of investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
